Innovative Cancer Drug Faces Time‑Crunch in Cost Review
The latest study looks at how well a new drug, pemigatinib, works for patients with a rare liver cancer called intrahepatic cholangiocarcinoma. Researchers evaluated whether the drug’s benefits are worth its price compared to other treatments. The analysis starts by measuring how many months patien